Estimating The Economic and Clinical Benefits of Mirabegron Versus Antimuscarinics for The Treatment of Overactive Bladder (OAB) in The United Kingdom (UK)
Abstract
Authors
J Nazir M Berling C McCrea F Fatoye Z Hakimi A Wagg
J Nazir M Berling C McCrea F Fatoye Z Hakimi A Wagg
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now